9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$329M | — | — | -$266M | $223M | $312M |
| 2024 | — | -$256M | — | — | -$208M | $0 | $98M |
| 2023 | — | -$192M | — | — | -$156M | — | $53M |
| 2022 | — | -$140M | — | — | -$126M | — | $140M |
| 2021 | — | -$72M | — | — | -$60M | — | $220M |
| 2020 | $8M | -$75M | 0.0% | -1044.3% | — | — | $242M |
| 2019 | $22M | -$32M | 0.0% | -143.0% | -$42M | — | $37M |
| 2018 | $10M | -$35M | 0.0% | -369.9% | -$33M | — | $56M |
| 2017 | $8M | -$25M | 0.0% | -312.8% | -$27M | — | $28M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$97M | — | — | -$87M | $223M | $241M |
| Dec '25 | — | -$102M | — | — | -$80M | $223M | $312M |
| Sep '25 | — | -$81M | — | — | -$64M | $44M | $125M |
| Jun '25 | — | -$74M | — | — | -$55M | $44M | $128M |
| Mar '25 | — | -$72M | — | — | -$67M | — | $126M |
| Dec '24 | — | -$68M | — | — | -$61M | $0 | $98M |
| Sep '24 | — | -$71M | — | — | -$52M | — | $97M |
| Jun '24 | — | -$59M | — | — | -$43M | — | $88M |
| Mar '24 | — | -$58M | — | — | -$53M | — | $216M |
| Dec '23 | — | -$54M | — | — | -$44M | — | $53M |
| Sep '23 | — | -$55M | — | — | -$38M | — | $87M |
| Jun '23 | — | -$44M | — | — | -$33M | — | $214M |
| Mar '23 | — | -$39M | — | — | -$41M | — | $161M |
| Dec '22 | — | -$40M | — | — | -$31M | — | $140M |
| Sep '22 | — | -$35M | — | — | -$38M | — | $141M |
| Jun '22 | — | -$35M | — | — | -$28M | — | $326M |
| Mar '22 | — | -$31M | — | — | -$29M | — | $191M |
| Dec '21 | — | -$25M | — | — | -$21M | — | $220M |
| Sep '21 | — | -$19M | — | — | -$15M | — | $203M |
| Jun '21 | — | -$17M | — | — | — | — | $218M |
Over the past 5 years, Cogent Biosciences, Inc.'s revenue has declined 2.0% per year. These are computed facts, not advice.
As of FY2025, Cogent Biosciences, Inc. reported $223M of total debt against $312M of cash; operating income covered interest expense -108.9×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.